公开(公告)号：US11053243B2

公开(公告)日：2021-07-06

申请号：US16829878

申请日：2020-03-25

申请人： Merck Sharp & Dohme Corp.

发明人： Craig A. Coburn ,  Steven W. Ludmerer ,  Kun Liu ,  Hao Wu ,  Richard Soil ,  Bin Zhong ,  Jian Zhu

IPC分类号： C07D471/04 ,  C07D407/14 ,  C07D487/04 ,  C07D401/14 ,  C07D403/14 ,  C07D403/12 ,  C07D413/14 ,  C07D405/14 ,  C07D405/12 ,  C07D417/14 ,  C07D409/14 ,  A61K31/4985 ,  A61K31/4439 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/4025 ,  A61K31/519 ,  A61K31/404 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/427 ,  A61K31/4245 ,  A61K31/475 ,  A61K31/536 ,  A61K31/4178 ,  A61K31/517 ,  A61K31/5386 ,  A61K31/553 ,  A61K31/437

摘要： The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.